GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for HOPE - 3

HOPE - 3

Official Title

Heart Outcomes Prevention Evaluation-3

Status

Ongoing

Overview

To evaluate whether a cholesterol lowering drug, rosuvastatin, and a combination blood pressure lowering pill, candesartan/ hydrochlorothiazide, used alone or together can reduce the risk of heart attack, stroke and their sequelae in people without known heart disease at average risk. The largest ongoing trial evaluating the polypill concept in primary prevention, expected to have a significant impact on primary prevention strategies globally.

Study Design

Randomized, double-blind, placebo control, factorial assignment, safety/efficacy study.

Primary Endpoint

Co-Primary endpoints: 1) The composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke. 2) The composite of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, heart failure and arterial revascularizations. Secondary endpoints are: total mortality and the components of the co-primary endpoints. Additional endpoints include progression of renal disease, new diagnosis of diabetes, cognitive function and erectile dysfunction in men. All primary and secondary endpoints are adjudicated.

Number of Patients

12705

Number of Sites

228

Number of Countries

21

Study Period

2007-2015

Principal Investigator

Salim Yusuf, Eva Lonn

Program Manager

Jackie Bosch

Research Coordinator

Joanne Wilkinson

Collaborators

AstraZeneca